Are hydrogels suitable for delivery of cisplatin to the microenvironment in breast cancer treatment: a meta-analysis.

IF 2.2 Q2 PHARMACOLOGY & PHARMACY

Therapeutic delivery Pub Date : 2025-10-09 DOI:10.1080/20415990.2025.2570632

Amir Hossein Izadi Nazar, Roya Safari Faramani, Yasin Roushani Roudsari, Faranak Aghaz

{"title":"Are hydrogels suitable for delivery of cisplatin to the microenvironment in breast cancer treatment: a meta-analysis.","authors":"Amir Hossein Izadi Nazar, Roya Safari Faramani, Yasin Roushani Roudsari, Faranak Aghaz","doi":"10.1080/20415990.2025.2570632","DOIUrl":null,"url":null,"abstract":"Background: Breast cancer is the most commonly diagnosed cancer for women. Cisplatin is one the most potent chemotherapeutic drugs we know in breast cancer, but its systemic toxicity limits its clinical application. Hydrogels are a local drug delivery system that limits the systemic toxicity of drugs and improves their efficacy.Objectives: This systematic review and meta-analysis evaluated the preclinical efficacy of cisplatin-loaded hydrogels for breast cancer treatment.Methods: We had a systematic search on different databases, including PubMed, Scopus, MEDLINE, Embase, Google Scholar, and the Web of Science, to find relative papers.Results: There was no statistically significant difference in cell viability between the cisplatin-loaded hydrogel and free cisplatin groups. However, the IC50 values were significantly higher in the treatment group, which means the cytotoxicity was reduced in the cisplatin-loaded hydrogel; then, we subgrouped them based on cell line and treatment duration; no significant difference was observed between the subgroups.Conclusions: This meta-analysis evaluated cisplatin-loaded hydrogels versus free cisplatin in breast cancer treatment. Contrary to expectations, no significant difference in cell viability was found, indicating hydrogels did not enhance therapeutic efficacy. However, a significantly higher IC50 with hydrogels suggests reduced instantaneous drug concentration due to sustained release.Prospero: CRD42025641451.","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"1-12"},"PeriodicalIF":2.2000,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic delivery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20415990.2025.2570632","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Breast cancer is the most commonly diagnosed cancer for women. Cisplatin is one the most potent chemotherapeutic drugs we know in breast cancer, but its systemic toxicity limits its clinical application. Hydrogels are a local drug delivery system that limits the systemic toxicity of drugs and improves their efficacy.

Objectives: This systematic review and meta-analysis evaluated the preclinical efficacy of cisplatin-loaded hydrogels for breast cancer treatment.

Methods: We had a systematic search on different databases, including PubMed, Scopus, MEDLINE, Embase, Google Scholar, and the Web of Science, to find relative papers.

Results: There was no statistically significant difference in cell viability between the cisplatin-loaded hydrogel and free cisplatin groups. However, the IC50 values were significantly higher in the treatment group, which means the cytotoxicity was reduced in the cisplatin-loaded hydrogel; then, we subgrouped them based on cell line and treatment duration; no significant difference was observed between the subgroups.

Conclusions: This meta-analysis evaluated cisplatin-loaded hydrogels versus free cisplatin in breast cancer treatment. Contrary to expectations, no significant difference in cell viability was found, indicating hydrogels did not enhance therapeutic efficacy. However, a significantly higher IC50 with hydrogels suggests reduced instantaneous drug concentration due to sustained release.

Prospero: CRD42025641451.

查看原文本刊更多论文

水凝胶是否适合在乳腺癌治疗的微环境中递送顺铂：一项荟萃分析。

背景：乳腺癌是女性最常见的癌症。顺铂是目前已知治疗乳腺癌最有效的化疗药物之一，但其全身毒性限制了其临床应用。水凝胶是一种局部给药系统，限制了药物的全身毒性，提高了药物的疗效。目的：本系统综述和荟萃分析评估了顺铂负载水凝胶治疗乳腺癌的临床前疗效。方法：系统检索PubMed、Scopus、MEDLINE、Embase、谷歌Scholar、Web of Science等数据库，查找相关文献。结果：载顺铂水凝胶组与游离顺铂组细胞活力差异无统计学意义。然而，治疗组的IC50值明显更高，这意味着顺铂负载水凝胶的细胞毒性降低；然后根据细胞系和治疗时间进行分组；亚组间无显著差异。结论：这项荟萃分析评估了顺铂负载水凝胶与游离顺铂在乳腺癌治疗中的作用。与预期相反，细胞活力没有发现显著差异，表明水凝胶没有增强治疗效果。然而，水凝胶的IC50显著提高表明，由于缓释，瞬时药物浓度降低。普洛斯彼罗:CRD42025641451。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutic delivery PHARMACOLOGY & PHARMACY-

CiteScore

5.50

自引率

0.00%

发文量

期刊介绍： Delivering therapeutics in a way that is right for the patient - safe, painless, reliable, targeted, efficient and cost effective - is the fundamental aim of scientists working in this area. Correspondingly, this evolving field has already yielded a diversity of delivery methods, including injectors, controlled release formulations, drug eluting implants and transdermal patches. Rapid technological advances and the desire to improve the efficacy and safety profile of existing medications by specific targeting to the site of action, combined with the drive to improve patient compliance, continue to fuel rapid research progress. Furthermore, the emergence of cell-based therapeutics and biopharmaceuticals such as proteins, peptides and nucleotides presents scientists with new and exciting challenges for the application of therapeutic delivery science and technology. Successful delivery strategies increasingly rely upon collaboration across a diversity of fields, including biology, chemistry, pharmacology, nanotechnology, physiology, materials science and engineering. Therapeutic Delivery recognizes the importance of this diverse research platform and encourages the publication of articles that reflect the highly interdisciplinary nature of the field. In a highly competitive industry, Therapeutic Delivery provides the busy researcher with a forum for the rapid publication of original research and critical reviews of all the latest relevant and significant developments, and focuses on how the technological, pharmacological, clinical and physiological aspects come together to successfully deliver modern therapeutics to patients. The journal delivers this essential information in concise, at-a-glance article formats that are readily accessible to the full spectrum of therapeutic delivery researchers.